BME100 s2015:Group12 12pmL1: Difference between revisions
Line 40: | Line 40: | ||
*Group 4 – 2 mg | *Group 4 – 2 mg | ||
*Group 5 – 0 mg (placebo, control group) | *Group 5 – 0 mg (placebo, control group) | ||
Beginning with 8 mg of lipopolysacchiride (since 10 mg have shown to increase levels of inflammotin), each group is given a sample that differs in dosage for each group. If the results for each test consistently show an increase in inflammotin levels , the team can narrow down on the dosage level of LPS where the inflammotin levels are beginning to approach stagnation (they do not increase, nor decrease), but are still increasing. This could potentially be the appropriate method for closing in on the minimal level of LPS required to increase the levels of inflammotin (the Goldilocks Zone) by locating the range of dosage values; given the financial restraints for the lab, the team could possibly conduct a second experiment on the range of LPS dosage values where the inflammotin levels approach this stage described, using the decimal increment of 0.5. | |||
'''Age'''<br> | '''Age'''<br> |
Revision as of 14:05, 25 January 2015
BME 100 Spring 2015 | Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help | |||||
OUR TEAMLAB 1 WRITE-UPWARNING: All material presented here is highly suspectible to change by the write-up's authors. Final draft will be complete by Tuesday, 11:59 P.M. Independent and Dependent VariablesIndependent Variable: Lipopolysacchride (LPS) would be the variable the research team changes, because according to the ELISA data analysis provided, the levels of inflammotin in the blood sample analyzed were affected by a determined amount of the drug, 10 mg. The team will be able to deduce how inflammotin levels interact with a certain dosage of LPS by manipulating this variable. Dependent Variable: Inflammotin is the protein responsible for inflammation and is the central part of the experiment the team will conduct. This variable will fluctuate based on the dosage of LPS the research team will administrator to the test groups. Experimental DesignGroups
Beginning with 8 mg of lipopolysacchiride (since 10 mg have shown to increase levels of inflammotin), each group is given a sample that differs in dosage for each group. If the results for each test consistently show an increase in inflammotin levels , the team can narrow down on the dosage level of LPS where the inflammotin levels are beginning to approach stagnation (they do not increase, nor decrease), but are still increasing. This could potentially be the appropriate method for closing in on the minimal level of LPS required to increase the levels of inflammotin (the Goldilocks Zone) by locating the range of dosage values; given the financial restraints for the lab, the team could possibly conduct a second experiment on the range of LPS dosage values where the inflammotin levels approach this stage described, using the decimal increment of 0.5. Age Age limit is between 60 to 70 years of age. The research team believes this is the prime demographic of elderly individuals whose personal health is adequate. These individuals are less likely to succumb to biological factors such as cell decay or organ failure, often from 71 years of age and older. Such issues may complicate the experiment.
10 subjects for each group, totaling 5 groups.
Subject Selection
Sources of Error and Bias
|